# Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)

> **NCT00493129** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 8 (actual)

## Conditions studied

- Leukemia
- Systemic Mastocytosis

## Interventions

- **DRUG:** Ontak (Denileukin Diftitox)

## Key facts

- **NCT ID:** NCT00493129
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** 2007-08
- **Final completion:** 2007-08
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2012-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00493129

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00493129, "Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00493129. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*